The effectiveness of the treatment of psoriasis with IL-17 inhibitor in a patient with concomitant obesity: a clinical case
I.S. Vladimirova (1), I.O. Smirnova (2, 3)
1) Dermatovenerologic Dispensary № 10 – Clinic of Dermatology and Venereology, St. Petersburg, Russia;
2) St. Petersburg State University, St. Petersburg, Russia;
3) City Dermatovenerologic Dispensary, St. Petersburg, Russia
Background. Obesity is one of the most common comorbid diseases in patients with psoriasis. It is assumed that systemic inflammation in obesity is accompanied by the release of adiponectin and pro-inflammatory cytokines, including key cytokines of psoriasis – interleukin-17 (IL-17) and IL-23, which in turn act as triggers for psoriasis and thereby can provoke its more severe course. In addition, obesity can reduce the effectiveness of drugs, including genetically engineered biologic drugs.
Description of the clinical case. The article describes the observation of a patient with severe plaque psoriasis and concomitant obesity treated with IL-17 inhibitors with a good clinical effect. Against the background of a decrease in body weight, a stable remission of the disease for a year and a half after the cessation of therapy was noted.
Conclusion. The treatment of psoriasis requires an integrated approach and the choice of treatment method. Obesity, one of the most common concomitant diseases, can not only interfere withthe achievement of the drug effect, but also aggravate the course of other comorbid conditions. It is important to choose a method of therapy that can pathogenetically affect psoriasis and obesity, for example, IL-17 inhibitors.
Keywords: psoriasis, obesity, quality of life, systemic therapy, genetically engineered biologic drugs
About the Autors
Corresponding author: Irina S. Vladimirova, Cand. Sci. (Med.), Dermatovenerologist, Dermatovenerologic Dispensary № 10 – Clinic of Dermatology and Venereology, St. Petersburg, Russia
Address: 29, lit. A, St. Petersburg 194021, Prospekt Parkhomenko, Russian Federation